Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
XENE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.53B
- EPS (TTM)
- -$4.74
- Dividend yield
- None
- 52-week range
- 35.75 – 72.66
- Day range
- 35.78 – 36.56
- Volume / Avg
- 1.97M / 1.47M
- Beta
- —
- Shares outstanding
- 96.84M
- Next earnings
- Nov 2, 2026
52-week range
XENE stock today
Shares of Xenon Pharmaceuticals (XENE) finished lower on Oct 7 at $36.41, a drop of 0.44% or $0.16 per share, versus the S&P 500's 0.22% decline. At this level, XENE sits near the bottom of its 52-week range of $35.75 to $72.66: 49.9% below the high, set on Jul 9, 2026 and 1.8% above the low. XENE is down 18.8% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 7.0%.
Xenon Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$4.74), so its P/E ratio is not meaningful. Xenon Pharmaceuticals's next earnings report is expected on Nov 2, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Xenon Pharmaceuticals
Company profileXenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.
- Headquarters
- Burnaby, BC
- Employees
- 358
- IPO year
- 2014
- Website
- xenon-pharma.com
Analyst forecast
ForecastConsensus (19 analysts)
strong_buy
Avg. price target
$73.37+101.51%
- Strong buy 3
- Buy 15
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 2, 2026
- EPS estimate
- $-1.17
Xenon Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PBLSParabilis Medicines Inc. | 28.82 | -0.14% | $3.56B | vs XENE |
| IDYAIDEAYA Biosciences Inc. | 36.26 | -1.01% | $3.50B | vs XENE |
| OGNOrganon & Co. | 13.79 | +0.36% | $3.62B | vs XENE |
| VKTXViking Therapeutics Inc. | 28.54 | +0.56% | $3.63B | vs XENE |
| AMLXAmylyx Pharmaceuticals Inc. | 27.43 | -2.18% | $3.44B | vs XENE |
| TNGXTango Therapeutics Inc. | 21.83 | -0.32% | $3.68B | vs XENE |
| ACADACADIA Pharmaceuticals Inc. | 19.65 | -0.46% | $3.39B | vs XENE |
| LEGNLegend Biotech Corporation ADR | 19.12 | +2.14% | $3.72B | vs XENE |
Indexes, lists and sector
Xenon Pharmaceuticals stock FAQ
What is Xenon Pharmaceuticals's stock price today?
XENE last traded at $36.41 as of Oct 7, 4:00 PM EDT, down 0.44% on the day. Prices are delayed at least 15 minutes.
When is Xenon Pharmaceuticals's next earnings date?
Xenon Pharmaceuticals is expected to report earnings on Monday, November 2, 2026. Analysts expect EPS of $-1.17.
Who is Xenon Pharmaceuticals's CEO?
Mr. Ian C. Mortimer C.M.A., CPA, M.B.A. is the chief executive officer of Xenon Pharmaceuticals Inc., which has about 358 employees.
What is the XENE 52-week high?
The 52-week high for XENE is $72.66 and the 52-week low is $35.75. The stock is currently 49.9% below its high.